Malaria continues to be one of the most virulent infectious diseases and accounts for the death of ~0.65 million people a year. Unlike most viral infections, children usually have repeated clinical episodes, but by adulthood, most individuals living in endemic areas are protected against disease. Immunoglobulin (Ig) molecules isolated from a protected adult can be used to passively transfer protection to nave individuals indicating a key role for antibody-mediated immunity. Cellular immunity mediated by CD8 T-cells and IFN? has also been implicated in protection against the initial liver stages of the infectionin experimental models, but the significance of this type of immunity during natural human infections has been difficult to evaluate. Rigorous analysis of protective immune responses in the field is hindered by an inability to control and define parasite exposure. Animal studies, whil allowing strain and inoculation controls, are difficult to apply to human infections due to differences across host and parasite species. The goal of the present study is to systematically evaluate the immune response to an initial Plasmodium falciparum (Pf) infection and 3 subsequent Pf infections in 10 healthy volunteers, each serving as their own control. The use of the human malaria challenge model allows the timing of parasite exposure to be controlled and therefore the early response to infection can be directly monitored. The 10 volunteers will first be challenged with uninfected mosquitoes to establish a baseline and then 4 sequential exposures to Pf-infected mosquitoes. Clinical symptoms will be monitored daily and the volunteers will be treated with standard dose of Coartem at the first positive malaria smear or on day 20 if no parasites are observed by then. Blood samples will be collected for transcription profiling, PBMC immunophenotyping and plasma characterization prior to and every 2 days after the challenge until treatment or day 20, if no parasites are observed. Additionally, plasma cells will be collected on day 20 1 for Ig repertoire evaluation. This systematic study of the clinical and immune response to repeated Pf infections will provide insights that can be used to design more effective intervention and control strategies.

Public Health Relevance

Despite over a half a century of effort, no effective vaccines have been developed against malaria, which still causes in over 650,000 deaths a year, primarily in children. The proposed study examines the development and maturation of the cellular and humoral immune responses following sequential parasite exposures. The data will be compared with the corresponding clinical course to identify factors associated reductions in fever and parasitemia. The findings will be used to design new immunization strategies to facilitate the development of an effective immune response.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI110852-06
Application #
9645591
Study Section
Vaccines Against Microbial Diseases Study Section (VMD)
Program Officer
Deye, Gregory A
Project Start
2015-03-01
Project End
2021-02-28
Budget Start
2019-03-01
Budget End
2021-02-28
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Henry M. Jackson Fdn for the Adv Mil/Med
Department
Type
DUNS #
144676566
City
Bethesda
State
MD
Country
United States
Zip Code
20817
Panackal, Anil A; Williamson, Kim C; van de Beek, Diederik et al. (2016) Fighting the Monster: Applying the Host Damage Framework to Human Central Nervous System Infections. MBio 7:e01906-15